Mylotarg

Indicated For

CD33-positive acute myeloid leukemia (AML)

About This Medication

# Pfizer Oncology Together Patient Guide: How to Get Mylotarg (gemtuzumab ozogamicin) at Low or No Cost Mylotarg (gemtuzumab ozogamicin) is a targeted therapy used to treat certain types of **acute myeloid leukemia (AML)**, a cancer of the blood and bone marrow. The **Pfizer Oncology Together** program helps eligible patients access Mylotarg through **co-pay assistance** for those with commercial insurance or **free medication** for uninsured or low-income patients via Pfizer RxPathways. ## About Mylotarg Mylotarg is indicated for newly diagnosed **CD33-positive AML** in adults and relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older. It works by delivering a chemotherapy agent directly to cancer cells expressing the CD33 protein on their surface. Administered as an intravenous infusion, typically over 2 hours, it is often used alone or in combination with other chemotherapy drugs like daunorubicin and cytarabine. **Important Safety Note**: Mylotarg carries a boxed warning for hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS). Doctors monitor liver function (ALT, AST, total bilirubin, alkaline phosphatase) before each dose and watch for VOD symptoms post-treatment. Premedication is given before infusions to prevent reactions, and vital signs are monitored during and after administration. For patients with adverse-risk cytogenetics, benefits and risks should be discussed once results are available. Always follow your doctor's guidance, as treatment plans are personalized based on your AML type, age, and health status. ## Who Qualifies for Pfizer Oncology Together? This program offers **two main paths**: 1. **Co-Pay Savings Program (for Injectables)**: For **commercially insured** patients. Eligible patients may pay **as little as $0 per month**, with up to **$10,000 in annual savings per product**. You must: - Have commercial (private) insurance. - Not be on government insurance like Medicare, Medicaid, or VA/military coverage. - Not receive Social Security Disability or other SSA benefits. - Agree to program terms. 2. **Patient Assistance Program (Pfizer RxPathways)**: For **uninsured or underinsured/low-income** patients. Provides **free medication**: - Up to **90-day supply** while applying for Medicaid. - Up to **1-year supply** if you don't qualify for Medicaid. - Uninsured: Free for up to 1 calendar year. - Underinsured: Through end of calendar year. Eligibility is based on **insurance status and financial need**. Specific income thresholds (e.g., Federal Poverty Level percentages) are not detailed publicly; call (877) 744-5675 to check. ## Income Eligibility Breakdown Income details vary by path and are assessed case-by-case. Here's a summary: | Patient Type | Income Threshold | Key Notes | |-------------|------------------|-----------| | **Commercially Insured** | Not income-based | Focus on insurance; financial need reviewed for co-pay help. Up to $10,000 savings/year. | | **Uninsured/Low-Income** | Financial need required | Free meds up to 1 year; no specific FPL % listed. Assessed via proof of income. | | **Underinsured** | Financial need required | Free through year-end; Medicaid applicants get 90 days. | | **Medicare/Medicaid** | Typically ineligible for co-pay | May qualify for free meds via RxPathways if low-income. | Contact the program for a **personal eligibility check**—they verify benefits and household income. ## Insurance Requirements - **Commercial Insurance**: Eligible for co-pay card reducing out-of-pocket costs to $0 (limits apply). - **Government Insurance (Medicare, Medicaid, VA)**: **Ineligible for co-pay assistance**. Uninsured/low-income patients can access free medication through RxPathways. - **No Insurance**: Qualify for free supply based on financial need. Pfizer Oncology Together performs **benefit verification** to confirm coverage. ## Step-by-Step Application Process Applications can be submitted **multiple ways**—online, phone, fax, mail, or provider portal. 1. **Gather Documents**: - Proof of income (e.g., tax returns, pay stubs). - Proof of insurance (or lack thereof). - Prescription for Mylotarg. - Diagnosis confirmation (e.g., lab results showing CD33-positive AML). 2. **Enroll**: - **Phone**: Call (877) 744-5675 (Mon-Fri, 8 AM–8 PM ET) for help. - **Online**: Visit pfizeroncologytogether.com/patient/sign-up or Provider Portal (pfizeroncologytogetherportal.com). - **Forms**: Download enrollment form; HCP and patient sign. - **Fax**: 1-877-736-6506. - **Mail**: Pfizer Oncology Together, PO Box 220366, Charlotte, NC 28222-0366. - **Upload**: patientsupportnow.org (code: 8777366506). 3. **Submit Claims (for Co-Pay)**: HCP submits via PfizerCopay.com within **180 days** of treatment. Include Explanation of Benefits (EOB). 4. **Approval**: Receive letter with co-pay card or confirmation of free meds. Pfizer follows up on missing info. **Reauthorization Required**: Yes, for ongoing treatment—resubmit periodically. ## Timeline and Delivery - **Processing Time**: Not specified; expect follow-up calls for verification. Claims process quickly via portal. - **Delivery**: Shipped to **patient's home** or **physician's office**. Start early—bridge programs may provide interim supply. ## Alternatives if Denied - **Appeal**: Contact program for review. - **Pfizer RxPathways**: Separate free drug program for uninsured/low-income. - **Other Resources**: State programs, NeedyMeds, PAN Foundation, or hospital financial aid. - **No Biosimilars**: None available for Mylotarg. ## Disclaimer This guide is for informational purposes only and based on publicly available program details as of 2026. Eligibility, terms, and benefits can change—**always verify directly with Pfizer Oncology Together at (877) 744-5675**. Not a substitute for medical or financial advice. See full Mylotarg Prescribing Information, including Boxed Warning. Pfizer Inc. reserves rights; limits/terms apply.

Program information last verified: March 30, 2026